One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study
- 1 November 2007
- journal article
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 3 (3), 315-320
- https://doi.org/10.4244/eijv3i3a58
Abstract
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Keywords
This publication has 8 references indexed in Scilit:
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary StentsNew England Journal of Medicine, 2007
- Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials)The American Journal of Cardiology, 2006
- Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary StentsCirculation, 2005
- Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)The American Journal of Cardiology, 2005
- Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable PolymerCirculation, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- Oral Everolimus Inhibits In-Stent Neointimal GrowthCirculation, 2002